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Abstract
Safe liver resection is a vital element in the management of primary and secondary 
hepatic malignancies. The indications for resection have evolved Over time, and this has 
in part been due to the ability to improve the future liver remnant (FLR). This chapter 
reviews the current and future methods used for assessing the future liver remnant vol-
ume and function in order to minimize the risk of post-hepatectomy liver failure (PHLF). 
Current and evolving methods used in augmenting the future liver remnant are also con-
sidered. Since its introduction in the 1990s, portal venous embolization (PVE) has become 
the most widely used method of augmenting the FLR. The factors that affect hypertrophy 
following embolization as well as techniques used in portal venous embolization will be 
reviewed. Other methods of augmentation discussed include portal vein ligation (PVL) 
and the emerging method of associating liver partition and portal vein ligation for staged 
hepatectomy (ALPPS). The chapter also considers the various methods in the context of 
limiting tumour progression in the future liver remnant and attempts to integrate newer 
techniques such as ALPPS into current treatment algorithms.
Keywords: future liver remnant, volume, portal venous embolization, hypertrophy, 
liver function measurement, resectability
1. Introduction
Safe liver resection is a vital element in the curative management of primary and secondary 
hepatic malignancies. The ability to perform major liver resections relies on the capacity of the 
future liver remnant (FLR) to maintain normal liver function. The quality of the FLR may also be 
influenced by pre-existing liver disease and/or prior chemotherapy, thereby limiting the size of 
resection possible. Various methods have been utilized to assess the size and functionality of the 
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future liver remnant to avoid post-hepatectomy liver failure and, when major liver resections 
are being considered, techniques are available to increase the volume of the FLR.
The commonest indication worldwide for hepatic resection is to treat colorectal cancer 
metastatic to the liver, and overtime the criteria for surgical resectability of colorectal liver 
metastases has evolved (Table 1). Initially, surgically resectable colorectal liver metastases 
included low volume, unilobar disease of 1–3 metastases which could be resected with a 1 cm 
macroscopic margin and no evidence of extrahepatic disease [1]. More recently, the number 
or bilaterality of metastases is not in itself a contraindication provided they can be resected 
with a macroscopic margin with an adequate FLR [2], and increasingly the presence of local-
ized extrahepatic disease [2] is not an absolute contraindication to resection. However, the 
response of metastases to chemotherapy has emerged as an important prognostic factor for 
disease-free survival [3], and consequently, most patients now receive neoadjuvant treat-
ment prior to resection. These factors and a globally more aggressive policy of resection have 
increased the numbers of patients eligible for potentially curative therapy but placed new 
emphasis on the importance of accurate assessment of the volume and function of the FLR.
The aim of this chapter is to review currently available methods to assess the quality and 
volume of the FLR pre-operatively as well as summarizing the methods used to improve the 
FLR including pre-operative portal venous embolization (PVE) and associating liver partition 
and portal vein ligation for staged hepatectomy (ALPPS).
2. Pre-operative assessment of liver function
Whether the indication for liver resection is a primary or secondary liver malignancy in order 
for surgery to be successful, the patient must be able to tolerate the physical and psychological 
challenges of surgery and the FLR must be able to sustain liver function. A thorough history 
and examination should identify presence and extent of comorbidities [4]. The assessment 
Characteristics Historical indications Current indications
Tumour number <4 lesions Any
Lobes involved Unilobar Bilobar or unilobar
Size of tumour <5 cm Any
Extrahepatic disease None Treatable extrahepatic disease
Functional Liver Remnant Adequate Adequate or amenable to augmentation
Lymph node involvement No hepatic pedicle nodes No coeliac node involvement
Synchronicity Metachronous Metachronous or synchronous
Venous involvement No vena caval or hepatic venous 
involvement
Venous resection or reconstruction
Adapted from Sherman and Mahvi [2].
Table  1. Indications for surgical resection of liver metastases.
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should also include assessment of liver function tests, coagulation status, full blood count 
and platelet count, relevant tumour markers and cross-sectional radiology [4]. All radiology 
and clinical information should be reviewed in a multidisciplinary meeting and early input 
obtained from specialist services such as hepatology, interventional radiology and medical 
oncology.
2.1. Assessing liver function
2.1.1. Liver function tests
The assessment of liver function is complex and largely reliant on surrogate markers. Initial 
clinical assessment involves assessment for signs of overt liver disease such as jaundice, spi-
der naevi and palmar erythema. An initial set of liver function tests including measurement 
of plasma bilirubin, transaminases, γ-glutamyl transferase and alkaline phosphatase as well 
as albumin and prothrombin time should be performed [5]. Two commonly used scoring 
systems have been developed using these parameters to assess liver function and associated 
surgical risk.
2.1.2. Scoring systems
The Child-Pugh (CP) and Model for End-Stage Liver Disease (MELD) scores are the most 
widely used stratification scores used in making decisions regarding surgery in cirrhotic 
patient (Tables 2 and 3).
Factor 1 point 2 points 3 points
Bilirubin (μmol/L) <34 34–50 >50
Albumin (g/L) >35 28–35 <28
INR <1.7 1.7–2.2 >2.2
Ascites None Diuretic controlled Refractory
Encephalopathy None Grade I-II (medication 
controlled)
Grade III-IV (refractory)
Class A = 5–6 points, Class B = 7–9 points, Class C = 10–15 points.
INR; international normalized ratio.
Modified from Hanje and Patel [10].
Table 2. Child-Pugh score.
MELD = 3.78 × ln[serum bilirubin (mg/dL)] + 11.2 × ln[INR] + 9.57 × ln[serum creatinine (mg/dL)] + 6.43
Predicts development post-operative liver failure post-hepatectomy for hepatocellular carcinoma where a score >11 
is predictive of worse outcome. Maximum creatinine is 4.0 mg/dL. Patients dialysing twice within the last week are 
assigned the maximum creatinine.
Adapted from Hanje and Patel 2007 [10] and Cha 2012 [39].
Table 3. MELD score.
Assessment and Optimization of the Future Liver Remnant
http://dx.doi.org/10.5772/66139
167
The CP score has been in clinical use for several decades and is based on the patient’s albu-
min, bilirubin, coagulation studies, severity of ascites and encephalopathy [6]. Individuals are 
stratified to Child A, B and C, and these correspond to increasing risk of perioperative mortal-
ity as well as post-operative complications such as bleeding, infection, ascites, renal failure 
and hepatic failure [6] (Figure 1).
The MELD score originally used to predict mortality following transjugular intrahepatic por-
tosystemic shunt (TIPS) has since been extrapolated to stratifying liver transplant patients as 
well predicting perioperative mortality [6] (Figure 1).
2.2. Dynamic tests of liver function
These tests are based on complete hepatic clearance or metabolism of a substrate following 
intravenous administration and include indocyanine green (ICG) clearance as well as nuclear 
medicine techniques.
2.2.1. Indocyanine green clearance
ICG is the most widely discussed pre-operative test to assess liver function. Historically, the test 
entails intravenous administration of ICG with multiple blood samples taken at 15-min intervals 
to determine plasma clearance but has become easier to perform with the availability of non-
invasive bedside monitors [7]. ICG is a water soluble, inert tricarbocyanine with a hepatic extrac-
tion rate above 70%, and is almost completely excreted in its unchanged form by the liver [7].
Figure 1. Relative risk of perioperative complication or death with increasing Child-Pugh and MELD scores. Adapted 
from Hanje and Patel [10]. 
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Test results are most commonly expressed as percentage of ICG retained after 15 min (ICG-
R15), and however, they can also be reported as the plasma disappearance rate (ICG PDR) or 
as the ICG elimination rate constant [8] (Figure 2). The safety limit when expressed as ICG-
R15 varies from 14 to 20% [8].
The use of ICG is limited in the presence of hyperbilirubinaemia since uptake is by the same 
hepatic transporters [8] and will therefore artificially decrease ICG clearance. The test is also 
dependent on overall liver blood flow and is less reliable in those with non-flow-dependent 
liver diseases [8].
2.2.2. Nuclear Medicine
Scintigraphy has been used to provide quantitative information on total and regional liver 
function using a variety of radiolabelled probes.
2.2.2.1. 99mTc-Mebrofenin
Mebrofenin is the iminodiacetic acid (IDA) analogue with the highest specificity for hepato-
cytes [8, 9]. It is absorbed by hepatocytes and eliminated in the bile without biotransformation 
in a similar fashion to bilirubin [8, 9]. The rate of hepatocyte uptake of technicium-labelled 
mebrofenin can be quantitatively assessed using scintigraphy and rate of biliary excretion 
determined.
2.2.2.2. 99mTc-GSA
(99m)Tc-DTPA-galactosyl serum albumin (where DTPA is diethylenetriaminepentaacetic 
acid) binds to the asialoglycoprotein receptor found on the sinusoidal surface of the hepa-
tocyte[8]. 99mTc-GSA is an asialoglycoprotein analogue that is taken up only in the liver [8]. 
The uptake of this agent is not affected by hyperbilirubinaemia and can therefore still be used 
for liver function assessment in the cholestatic patient [8]. Scintigraphy permits assessment 
of hepatic uptake as measure of function, and 99mTc-GSA remains trapped in the liver which 
permits further assessment of liver volume. However, this agent is not widely available out-
side of Japan.
Figure 2. Indocyanine green plasma clearance curve obtained from serial blood sampling or optical pulse spectrophotometry. 
Retention at 15 min (arrow) is commonly used to assess liver function. Modified from Cha et al. [39]. 
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2.2.3. 13C-Methacetin Breath Test (LiMax)
The 13C-methacetin breath test is based on activity of the cytochrome P450 1A2 (CYP1A2) 
enzyme system [8]. The system is distributed throughout the liver and is not affected by 
drugs or genetic variation [8]. 13C-methacetin is exclusively metabolized by CYP1A2 into 
paracetamol and 13CO
2
 [10]. The test is performed by measuring 13CO
2
/12CO
2
 ratio in expired 
breath before and after administration of 13C-methacetin. The result is expressed in μg/kg/h 
and gives total liver function. If combined with computed tomographic (CT) scan, it may be 
used to approximate the function of a section of liver, and however, this assumes uniform 
distribution of hepatic function, and it is known that this may vary between segments [8].
3. Radiological measurement of liver volume
Multiple cross-sectional imaging modalities are available for imaging the liver and include 
ultrasound, CT and magnetic resonance imaging (MRI). Data obtained with these investiga-
tions can be used to volumetrically assess the FLR as well as define the presence and position 
of hepatic tumours and the presence of chronic liver disease.
3.1. Ultrasound
Transabdominal ultrasound is widely available, non-invasive and low cost. However, it is 
operator independent, and its accuracy may be affected by body habitus, the presence of ileus 
or ascites as well as the presence of diffuse hepatic disease and steatosis which may be seen 
following chemotherapy [11].
In patients with colorectal liver metastases, the sensitivity of lesion-by-lesion analysis ranges 
from 60.9 to 64.9%. The specificity ranges from 50 to 60%, and the range increases from 76.7 
to 83.3% with the use of contrast [11]. The increased sensitivity of contrast-enhanced US (80–
90%) makes it useful in guiding the percutaneous biopsies of lesions [11].
Three-dimensional ultrasound probes are available, but the use of transabdominal ultrasound 
in hepatic volumetry assessment remains limited by the previously stated problems of body 
habitus and operator expertise [12]. Ultrasound is also routinely used intraoperatively where 
it may identify occult liver metastases denoting unresectable disease in up to 25% of patients 
[13] but currently has no role in assessing FLR volume.
3.2. Computed tomography (CT)
CT has become widely available and is relatively inexpensive. It offers the ability not only to 
detect lesions, but also to detect accurately localize lesions as well as their vascular and biliary 
relations [11]. It does involve exposure to ionizing radiation and the risk of allergic reactions 
to iodinated contrast [11]. The lesion-by-lesion sensitivity is up to 75% [11] although the rate 
of detection decreases with size of the lesion with a 16% detection rate for lesions smaller 
than 10mm in diameter [11]. The ability to construct three-dimensional (3D) models from the 
images allows for more accurate planning of surgical resection and appreciation of intrahe-
patic vascular anatomy prior to resection [14].
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CT scan is also commonly used to estimate the volume of the FLR by directly quantifying the 
volume from scan acquired data. The FLR volume is measured by CT and then standardized 
to the total estimated liver volume (TELV) [15].
 TELV ( cm 3  ) = –794.41 + 1267.28 × BSA( m 2  ) 
The ratio of the CT measured FLR volume to the TELV is known as the standardized FLR 
(sFLR) that allows a uniform comparison of FLR volume before and after PVE [15]. More 
commonly, total liver volume can be measured using data acquired in the CT scan, and com-
parison is made with the directly measured volume of the FLR (Figure 3).
3.3. Magnetic resonance imaging (MRI)
MRI is the most accurate of the available modalities in detecting colorectal metastases as 
well as many other malignancies. It does not make use of ionizing radiation and gado-
linium-based extracellular agents or hepatocyte-specific contrast agents such as gadoxetic 
acid may be used as contrast [11]. Overall, the sensitivity of contrast-enhanced MRI is 94% 
for colorectal metastases[11] and is superior to CT scan in the detection of small lesions as 
well as lesions in steatotic livers [11]. MRI is not routinely used clinically to assess hepatic 
volumetry.
3.4. PET CT
Fluorodeoxyglucose positron emission tomography (18FDG PET) provides metabolic infor-
mation which when combined with CT provides a metabolic map of glucose uptake [16] that 
is highly specific for cancer. PET CT is less sensitive in the detection of hepatic lesions than 
CT or MRI but is more specific and is able to accurately define the presence of extrahepatic 
disease [16]. PET CT is not currently used to assess hepatic volumetry.
Figure 3. A: Axial CT scan showing solitary colorectal metastasis in segment 8 (arrow) with a congenitally small left lobe. 
B: Three-dimensional reconstruction and total liver volume (1531.20 ml) measured 6 weeks following right portal vein 
embolization. C: Three-dimensional reconstruction and total remnant volume (314.67 ml) measured 6 weeks following 
right portal vein embolization. The left-sided remnant now constitutes 20.5% of the total liver volume and the patient 
proceeded to right hepatic lobectomy. 
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4. Combined imaging and dynamic tests
As previously described, available imaging and liver function tests have a number of short-
comings with regard to estimation of function of the future liver remnant. This is impor-
tant since hepatic volume and hepatic function do not have a linear correlation. A number of 
groups have attempted to improve predictability of FLR volume and function by combining 
modalities (Table 4).
5. Definition of an adequate future liver remnant
With regard to the future liver remnant, an FLR ≤20% of total hepatic volume is the strongest 
predictor of hepatic insufficiency and is thus set as the minimum FLR volume for a healthy 
non-cirrhotic liver [17]. It has generally been regarded that those who have received che-
motherapy for longer than 12 weeks should have an FLR >30% of total hepatic volume and 
those with fibrosis or cirrhosis an FLR >40–50% of total hepatic volume [17]. However, it 
must be emphasized that patients with cirrhotic livers, even where FLR is adequate, remain 
at increased risk of wound breakdown, infection, ascites and fluid retention, as they would 
be for any major surgery.
The increased FLR requirement for patients who have received chemotherapy is based on 
the premise that pre-operative chemotherapy may cause liver damage or increase the risk of 
post-operative complications [18]. Treatment with irinotecan is associated with rates of ste-
atohepatitis as high as 20.2% compared to 4.4% in those not on chemotherapy [19]. Treatment 
with oxaliplatin is associated with hepatic sinusoidal injury that can result in venoocclusive 
disease and nodular regenerative hyperplasia [19]. There is greater morbidity following hepa-
tectomy in those with evidence of sinusoidal obstruction syndrome and a greater risk of peri-
operative blood transfusion [19].
However, the majority of investigations have shown (Table 5) that liver injury in the setting 
of neoadjuvant therapy does not appear to have significant clinical consequences if chemo-
therapy is maintained until a response is observed and disease is then resected as early as is 
feasible [20].
Group Modalities Outcome
Chapelle et al. [25] 99mTc-mebrofenin/FLRV Predicts future liver function after resection 
(eFLRF). Cut-off of 2.3%/min/m2 for eFLRF would 
have prevented all mortalities related to PHLF
Hwang et al. [40] FRL-kICG (derived ICG and CT volumetry) Appeared to predict PHLF risk quantitatively
De Graaf et al. [41] 99mTc-mebrofenin/SPECT No difference between actual FLR and predicted FLR
PHLF, post-hepatectomy liver failure. FRL-kICG is the ICG clearance rate constant (ICG-K) fraction of future remnant 
liver to total liver volume.
Table 4. Examples of combined modalities in FLR estimation.
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6. Augmentation of the future liver remnant
With advances in surgical technique and radiological imaging, more extensive liver resec-
tions have become feasible and the challenge remains the ability to maintain liver function 
post-operatively. Methods have been developed aiming to increase the size of the future liver 
remnant. These include portal venous embolization, portal vein ligation (PVL) and associat-
ing liver partition and portal vein ligation for staged hepatectomy (ALPPS). Augmentation is 
recommended where FLR is anticipated to be ≤20% for normal, ≤30% for those with chemo-
therapy associated steatohepatitis and ≤40–50% in those with cirrhosis [21].
6.1. Portal venous embolization
Portal venous embolization was developed to improve the size and function of the FLR in 
tumour bearing liver by occluding the ipsilateral portal vein, the non-tumour bearing con-
tralateral side, which is to be the FLR, increases in volume by a combination of hypertrophy 
and hyperplasia [22]. The capacity for regeneration in the otherwise healthy liver is signifi-
cant, and PVE results in increased FLR volume in roughly 60% of patients with the average 
increase in volume being 12% [17]. The response is variable, and the size of the FLR prior to 
PVE may predict the degree of hypertrophy [23]. There is evidence to suggest that the degree 
of hypertrophy is inversely proportional to the FLR ratio before PVE such that a smaller FLR 
will have a larger hypertrophy [24]. PVE is contraindicated in the presence of ipsilateral portal 
vein tumour thrombus or occlusion and in patients with severe portal hypertension [22].
Author Intervention No. Comparison FLR effect
Goéré et al. [42] PVE 20 ≥1 -month interval vs no interval None
Ribero et al. [43] PVE 112 Chemo vs no chemo None
Gruenberger et al. [44] Hepatectomy 52 None
Covey et al. [45] PVE 100 Chemo vs no chemo None
Aussilhou et al. [46] PVE 40 Chemo+bevacizumab/chemo 
without bevacizumab
Impaired FLR/none
Tanaka et al. [47] PVE/Hepatectomy 60 Chemo vs no chemo None
Sturesson et al. [48] PVE 26 Chemo vs no chemo Impaired FLR
Sturesson et al. [49] Hepatectomy 74 Chemo vs no chemo Impaired FLR
Beal et al. [50] Hepatectomy 72 Chemo vs no chemo
>6 cycles vs ≤6 cycles
None
Dello et al. [51] Hepatectomy 72 Chemo vs no chemo
>6 cycles vs ≤6 cycles
None
Fischer et al. [52] PVE 64 Chemo vs no chemo None
PVE, portal vein embolization; FLR, future liver remnant.
Adapted from Simoneau et al. [27].
Table 5. Effect of chemotherapy on liver hypertrophy.
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PVE may be performed under general anaesthesia or local anaesthesia with sedation, and the 
approach may be contralateral or ipsilateral [24]. The procedure is commonly used to occlude 
the right portal vein and induce left lobe hypertrophy. In the contralateral approach, the left 
portal vein is punctured to give access for embolization of the right portal vein [24]. The con-
tralateral approach is less technically demanding, and however, it does risk potential injury 
to the FLR [24]. Where extended right hepatectomy is considered, embolization of portal vein 
branches to segment IVa and IVb can be undertaken. A short segment (1 cm) of unembolized 
right portal vein may be left to allow for surgical ligation during resection [25].
Various agents have been used for embolization, and most are associated with adequate 
hypertrophy rates and acceptable complication profiles (Table 6).
The degree of FLR hypertrophy is also influenced by the health of the underlying liver. Non-
cirrhotic liver hypertrophies at a rate of about 12–21 cm3/day at 2 weeks compared to just 9 
cm3/day for a cirrhotic liver [22] and the growth rate can be used to predict the probability of 
liver failure and major complications [23] (Figure 4).
Figure 4. Nonparametric regression of measured future liver remnant growth rate to predict probability of liver failure. 
Minimal or negative remnant growth rate following portal vein embolization was associated with higher rates of post-
resection liver failure. Reproduced from Leung et al. [23] with permission. 
Embolic agent Authors No. of patients Increase FRL %
Gelatin sponge Fuji et al. [53]
Kusaka et al. [54]
Kazikawa et al. [55]
Nanashima et al. [56]
30
18
14
30
17.8
21.2
23.8
29.4
Polyvinyl alcohol + coils or plugs Covey et al. [44]
Van den Esschert et al. [57]
Libicher et al. [58]
100
10
10
24.3
26.1
26.4
N-butyl cyanoacrylate De Baere et al. [59]
Giraudo et al. [60]
Elias et al. [61]
Broering et al. [62]
107
146
68
17
57.8
41.7
59.1
69.4
Fibrin glue Nagino et al. [63]
Liem et al. [64]
105
15
27.4
31.4
Modified from Loffroy et al. [24].
Table 6. Hypertrophic response to embolic agents.
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While PVE is used for its effect on the contralateral lobe of liver, it has also been associated 
with tumour progression. Liver growth is regulated by a number of growth factors and cyto-
kines the up-regulation of which is known to be involved in multiple tumour pathways [26]. 
Other factors thought to contribute to tumour progression are the compensatory increased 
inflow via the hepatic artery and the cellular host response [26]. There are currently no spe-
cific therapies available aimed at limiting the effects of these growth factors and cytokines on 
tumour progression. However, two-stage hepatectomy or ablation can be used where disease 
in the FLR is resected or ablated prior to PVE or PVL [14].
The timing of definitive resectional surgery following PVE is not formally prescribed, and 
however, most investigations report repeating imaging (usually CT scan) at 4–6 weeks 
 following PVE and, if sufficient FLR volume has been achieved, undertaking resection soon 
afterward. Simoneau et al. demonstrated an increase of 1-day post-PVE increased the risk of 
tumour progression by 1% [27]. It has been suggested that earlier surgery such as 2 weeks 
after PVE may reduce the risk of tumour progression [26].
6.2. Portal vein ligation
PVL is undertaken operatively and often in the setting of staged hepatectomies where small 
tumours in the FLR are removed or ablated and open ligation of the right portal vein is per-
formed. Pandanaboyana et al. in their meta-analysis found that PVE and PVL had a mean 
percentage increase in FLR volume of 39% and 27%, respectively; however, this did not reach 
statistical significance [28]. They proposed that this may be explained the observation that 
the later formation of portoportal collaterals does not impact on liver hypertrophy as this is 
induced early after portal occlusion [28].
6.3. Associated liver partition and portal vein ligation
ALPPS was first performed in 2007 and was noted to result in significant hepatic hypertrophy 
with increased resectability in those with large tumours [29]. The procedure was performed 
during an exploration for hilar cholangiocarcinoma. A left hepaticojejunostomy was per-
formed to reduce cholestasis to the FLR, the liver was divided along the falciform ligament, 
and the right portal vein was ligated [29]. A CT scan performed 8 days later demonstrated a 
94% increase in FLR, and the resection was successfully completed the following day [29].
The classical ALPPS procedure for a large right-sided tumours involves right portal vein liga-
tion, ligation and division of the segment IV portal branches as well as transection of the liver 
parenchyma along the falciform ligament [29]. Any tumour deposits within the future liver 
remnant can also be resected or ablated at this time.
Associating liver tourniquet and portal ligation for staged hepatectomy (ALTPS) is a variation 
in which rather than dividing the liver parenchyma and ligating the portal vein, the effect 
of occluding portal flow and transection is achieved by use of tourniquet [29] and radiofre-
quency or microwave ablation may also be combined with portal vein ligation [29]. In an 
attempt to reduce surgical complications following the initial surgical procedure, a partial 
ALPPS in which parenchymal transection is not complete has also been described [29].
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The advantage ALPPS over two-stage hepatectomy is that it may improve the feasibility of 
resecting previously unresectable tumours owing to the very high FLR gains seen. The short 
time between the procedures makes tumour progression unlikely [30].
In 2012, the International ALPPS registry was formed to systematically collect data from mul-
tiple centres performing the procedure, and the first analysis was published in 2014 [31]. This 
analysis which included 202 patients, 70% of whom had an underlying diagnosis colorectal 
liver metastases, and reported a 90-day mortality of 9% [31] (Table 7). Independent risk fac-
tors for in hospital severe complications included patient age >60 years, tumours other than 
colorectal liver metastases as well as 2 markers of complex liver resection (stage 1 ALPPS 
procedure >5 h and/or the need for intraoperative blood transfusions) [31].
The data in Table 7 confirm that ALPPS is a physiologically demanding procedure, and there 
is a paucity of data concerning long-term outcomes. Buac et al. [32] recently conducted a sur-
vey of 66% of the surgeons contributing to the International ALPPS registry and noted that 
there was significant variability in the indications for surgery as well as how it is performed. 
Currently, PVE is widely used while ALPPS is still under investigation. Schadde et al. [31] 
published a head to head comparison of the two procedures (Table 8).
6.4. Assessment of liver remnant volume using ICG clearance intraoperatively during 
vascular exclusion (ALIIVE)
This is a newly reported intraoperative procedure, which may have the advantage of some 
planned ALPPS procedures occurring as a single-step hepatectomy as well as identifying the 
need for an ALPPS procedure where one had not been planned [33]. The technique involves 
non-invasive measurement of ICG PDR at 5 points during resectional surgery. Measurement 
occurs before anaesthetic induction (ICG 1), following mobilization of FLR (ICG 2), during 
inflow occlusion of the resection lobe (ICG 3), following parenchymal transection with inflow 
occlusion (ICG 4) and finally during inflow as well as outflow occlusion following parenchy-
mal transection (ICG 5/ALIIVE) [33].
The aim of this test is to replicate the post-resection state intraoperatively. Lau et al. published 
their initial experience and while their series was too small to deduce an ICG PDR cut-off 
level, they suggested that as the post-hepatectomy state was replicated, it was likely that pre-
viously demonstrated cut-off levels could be applied to the procedure [33]. Previous studies 
have suggested a PDR >9%/min would likely be safe, while a PDR <7%/min would confer 
a high risk of insufficiency [33]. Interestingly, the only mortality of the 10 patients had an 
ALIIVE ICG of 7.1%/min [33].
This procedure will require further validation studies, but could certainly spare some patients 
a second procedure or allow others the opportunity of an ALPPS procedure if not already 
planned pre-operatively.
6.5. Transarterial embolization (TAE)
Transarterial chemoembolization (TACE) is based on the concept that blood supply to tumour 
is generally derived from the hepatic artery [34]. Following portal venous embolization, the 
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Author Number of  
patients
Simultaneous  
colorectal  
resection
FLR  
hypertrophy %
Mean LOS Morbidity% Mortality % Follow-up  
days
DFS % OS%
Schnitzbauer et al. [65] 25 0 74 nr 68 12 60-776 80 86
Alvarez et al. [66] 15 3 78.4 19 53 0 18–410 73 100
Li et al. [67] 9 nr 87.2 nr 100 22 nr nr nr
Dokmak and Belghiti [68] 8 nr 70 42 90 nr nr nr nr
Machado et al. [69] 8 nr 88 nr nr 0 nr nr nr
Donati et al. [70] 8 nr 66–200 nr nr nr nr nr nr
Adriani et al. [71] 2 nr nr nr nr 0 912–1460 0 100
Govil [72] 1 nr nr nr nr nr nr nr nr
Oldhafer et al. [73] 1 0 nr nr nr 0 nr nr nr
Conrad et al. [74] 1 nr 45 nr 0 0 nr nr nr
Cavaness et al. [75] 1 0 100 13 nr 0 nr nr nr
Adapted from Alvarez et al. [76].
Nr, not reported; DFS, disease-free survival; OS, overall survival.
Table 7. Overview of hypertrophy, mortality and morbidity following ALPPS for various studies.
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hepatic arterial flow is increased and this is thought to preserve viability of the embolized lobe 
[35]. However, there may still not be adequate hypertrophy of the FLR, and it has been sug-
gested that further interruption of the vascular inflow (arterial occlusion) may result in further 
hypertrophy [35]. However, the near complete occlusion that occurs with PVE followed by TAE 
may induce parenchymal infarction, and this sequence currently has few applications [35].
Conversely, TAE followed by PVE has demonstrated safety in case of hepatocellular carci-
noma with inadequate FLR [35]. Unfortunately, this has not been useful in management of 
colorectal metastases as these tumours are generally not fed by an artery [35].
6.6. Radioembolization
Selective internal radiation therapy (SIRT) with Y-90 has generally been used as treatment for 
locally advanced liver tumours. A transarterial catheter is introduced, and Y-90 microspheres 
are infused to lodge at the tumour arteriolar level. The radioactive microspheres result in 
reduced blood flow to the tumour but also deliver Y-90 brachytherapy [36]. The reported rates 
of response are 42–70% for colorectal liver metastases [36] and, in addition to the local control 
of tumour, unilateral treatment has been noted to result in hypertrophy of the contralateral 
liver lobe [37]. The theoretical advantage of SIRT over PVE would then be that tumour pro-
gression might not continue unabated while awaiting hypertrophy of the FLR if SIRT were 
selectively administered. Teo et al. [36] in a systematic review found that, while the degree of 
hypertrophy from SIRT was comparable to that of PVE (26–47% vs 10–46%), the time interval 
over which growth occurred was much slower than that of PVE (44 days to 9 months vs 2–8 
weeks) making it less likely to be clinically useful.
6.7. Associating portal embolization and artery ligation (APEAL)
This procedure combines portal vein embolization and arterial ligation [38]. At the first stage 
of the procedure, the FLR is surgically mobilized as in the ALPPS procedure. The right portal 
vein is embolized before being ligated and divided [38]. A right sectoral hepatic artery liga-
tion is performed (either the artery for segments V/VIII or segments VI/VII), and the segment 
IVb inflow is also interrupted [38]. There is no parenchymal transection. The second, resection 
stage of the procedure is undertaken 1–2 months later.
Dupre et al. [38] published their series of 10 patients who had required two-stage extended 
right hemihepatectomy for bilobar colorectal metastases. All the patients included had a low 
FLR volume and/or prolonged pre-operative chemotherapy and the procedure resulted in 
Reason for failure PVE/PVL (n = 83) ALPPS (n = 48)
Perioperative death (90 days) % 6% 15%
No stage 2 due to tumour progression % 16% 0%
No stage 2 due to failure to grow% 7% 0%
R1 resection % 5% 2%
Failure to reach primary endpoint % 34% 17%
Table 8. Mortality and outcomes of ALPPS v PVE/PVL. Modified from Schadde et al. 2014 [31].
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FLR hypertrophy of over 100% at day 7 [38]. There were no complications related to hepatic 
necrosis, and the authors suggest that the avoidance of parenchymal dissection reduces the 
risk of bile leak and infection. The interval of 1–2 months between stages was chosen to allow 
for post-operative recovery and to identify those with rapidly progressive disease. Initial 
results suggest morbidity and mortality rates comparable to ALPPS and PVE, and however, 
more long-term results and further validation studies are required [38].
7. Conclusion
The indications for liver resection continue to evolve as do the improvements in radiological 
ability to assess disease extent and accurately measure FLR volume. This information enables 
surgical teams to precisely calculate perioperative risk and determine resectability—almost 
to the millimetre. There is an evolving use biochemical markers which, when combined with 
imaging, may improve the safety of surgery further by allowing not only for estimating the 
volume but also the function of the future liver remnant.
The development of surgical techniques such as ALPPS, ALIIVE as well as adjuncts to surgery 
such as PVE/PVL and perhaps SIRT are increasing the number of patients who can be con-
sidered to have resectable disease. This would not be possible in the absence of oncological 
advancements as well as improvement in perioperative care. As our imaging and functional 
assessment technology improves, current management algorithms will also evolve (Figure 5).
Figure 5. Example of future algorithm. ALIIVE technique could be utilized at the time of first stage hepatectomy or 
ALPPS to determine whether resection can be completed at first stage. 
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